I run a small set of bots for my own work. One scans pharma marketing news every morning. One keeps an eye on GA4. One tracks the questions patients ask and how AI answers them. One takes meeting notes. One follows clinical trials.
None of them is clever on its own. Each does one narrow job, every day, without getting bored. That’s the part that changed how I work. I spend less time collecting and more time deciding.
My guess is that by 2027 a biopharma digital marketing team will look similar, just bigger. Not one AI assistant. A workforce of specialized bots, each with a clear job, a clear handoff, and a person who signs off.
Here are the eight I’d build.
1. The AI answer watchdog
Watches: How ChatGPT, Gemini, Claude, Google AI Overviews and AI Mode, and OpenEvidence answer questions about your brand and condition. Daily, not once a quarter.
Hands off: Answers that drift off-label, leave out safety information, or cite a competitor where your brand should be.
Signs off: MLR and the brand lead decide what, if anything, to do about it.
2. The measurement watchdog
Watches: GA4 and the ad platforms for broken tags, imported conversions that don’t match reality, HCP traffic leaking into patient reporting, and micro-events quietly counted as conversions.
It also watches where AI traffic lands. Practitioner tracking reported by Search Engine Roundtable suggests Gemini stopped passing utm_source=gemini around late September 2026. Visits from iOS apps often arrive with no referrer at all. Both end up in Direct, and AI looks smaller than it is.
Hands off: A short list of what broke and when.
Signs off: The analytics lead, before anyone acts on the numbers.
3. The patient and caregiver question miner
Watches: Forums, Reddit, search data, and brand-site chat logs.
It isn’t looking for keywords. It’s looking for the barriers that keep people from starting a treatment or staying on it: cost confusion, side effect worries, injection fear, insurance hoops.
I noticed Veeva’s November 2026 Europe summit agenda lists BeOne presenting on using conversational AI insights from brand sites to find treatment barriers. That’s an agenda topic, not a published result, but it’s the right instinct.
Hands off: Themes and draft FAQ topics for the content team.
Signs off: Content strategy, then MLR.
4. The MLR pre-check
Watches: Drafts before they go to medical, legal, and regulatory review. Missing fair balance, unsupported claims, off-label language.
The case for this one is easy. According to a trade report (FDAweb) on OPDP director Twyla Mosey’s October 28, 2026 remarks at FDLI, OPDP issued 30 enforcement letters in fiscal 2026, 28 untitled and 2 warning letters, out of more than 172,000 submissions. The most common problems were omitting or minimizing risk, unsupported efficacy claims, and misstated indications. Per the report, she said many were avoidable.
Hands off: A marked-up draft with flags.
Signs off: The MLR committee. This bot pre-reviews. It never approves.
5. The machine-readable content bot
Watches: Whether your content works for an audience that doesn’t read like people do: AI systems. Structured on-label content, schema, robots.txt, and meta tags.
This is where small settings cause big problems. On October 30, 2026, Google, Microsoft, and OpenAI said they will honor a shared robots.txt token for opting out of AI training. Google says it will treat that opt-out like blocking Google-Extended, which also turns off grounding in Gemini Apps unless Google-Extended is explicitly allowed. So a blanket “no AI training” line, added with good intentions, can drop a brand out of Gemini answers.
Hands off: Audit findings and suggested fixes.
Signs off: The web team, with legal on anything touching AI access policy.
6. The paid media bot
Watches: Creative performance across Google AI Mode ads, ChatGPT Ads, and HCP platforms. ChatGPT Ads currently run only on the Free and Go tiers, and pharma eligibility isn’t stated, so that one is a watch item for now.
It rotates and tests approved creative, keeps HCP and patient campaigns strictly separate, and pauses Smart Bidding when it’s being fed noise instead of real conversions. That last part depends on bot 2 doing its job.
Hands off: Test results and recommended budget shifts.
Signs off: The media lead. Only approved creative goes in.
7. The competitive and regulatory monitor
Watches: Competitors’ presence in AI search, their ad copy, label updates, and new OPDP letters. Daily, not in a quarterly deck.
Hands off: A short daily note: what changed and why it might matter.
Signs off: Brand strategy decides whether anything changes.
8. The HCP briefing prep bot
Watches: What a doctor’s specialty is asking AI tools, recent publications, and payer changes, so reps and MSLs walk in prepared.
This matters more each year. Bain’s October 2026 survey of 400 US physicians, fielded in June 2026, found 20% rank AI among their top three sources of prescribing information, compared with 3% in December 2024. If doctors are asking AI first, the people who visit them should know what AI is telling them.
Hands off: A one-page brief before the visit.
Signs off: The rep or MSL, plus the usual compliance rules on what they can discuss.
Where people stay in charge
Writing these out, I notice the “signs off” line matters more than the “watches” line.
Bots don’t approve claims. They don’t set strategy. They don’t diagnose anyone, and they don’t talk to patients without review. In a regulated industry those lines aren’t a formality. They’re the job.
What bots change is the prep. The checking, scanning, and first drafts that used to eat a team’s week can happen every morning before anyone logs in. That leaves senior people to do the part that needs judgment.
That’s the model I believe in: senior judgment, backed by automated prep. It’s also how we work at PharmaForward.